Inamed Acquires License Rights to Juvederm, a Non-Animal-Based, Cross-Linked Hyaluronic-Acid Line of Dermal Filler Products

Exclusive rights to Juvederm family of products in North America and Australia, with non-exclusive rights in key European markets

Rights to future hyaluronic acid product line extensions

Products expand Inamed leadership and comprehensive offering of facial rejuvenation products in key markets around the world

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Jan. 12, 2004--Inamed Corporation (Nasdaq:IMDC): Inamed Corporation (Nasdaq:IMDC), a global health care company, today announced the signing of licensing agreements with Corneal Group for the rights to develop, distribute and market the Juvederm(R) dermal fillers family of products in specified markets around the world. Juvederm is a full range of products based on non-animal, cross-linked hyaluronic acid technology. The agreements include current formulations of Juvederm as well as future hyaluronic acid product line extensions.

Under these agreements, Inamed will have the exclusive rights to develop, market and distribute the Juvederm products in the United States, Canada and Australia, and non-exclusive rights in France, Spain, the United Kingdom, Italy, Germany and Switzerland. In the non-exclusive European countries, Inamed will establish a new brand name to promote and market Juvederm. Juvederm products are currently approved or registered in over 36 countries, including all major European markets.

Like CosmoDerm(TM) and CosmoPlast(TM) human collagen and Hylaform(R) Gel hyaluronic acid -- also Inamed products -- Juvederm does not require a pre-treatment skin test in the countries where it is currently approved and marketed.

"We are pleased to be working with a partner such as Corneal to strengthen our global leadership position in the area of facial rejuvenation and aesthetics," said Nick Teti, Chairman, CEO and President, Inamed Corporation. "In countries where the Juvederm family of products is available it has rapidly become a reliable part of physicians' array of dermal fillers used for facial rejuvenation."

"The Juvederm products are well respected around the world," said Waldemar Kita, President, Corneal Group. "We wanted a licensing partner with exceptional experience and capabilities who we could trust with our products' reputation, as well as the faith of our medical professionals and patients. Inamed is the most qualified partner globally, and we're excited to work with them to bring these products to more patients worldwide."

The family of Juvederm products was introduced in 2000 in Europe and in 2002 in Canada, where it was rapidly adopted by physicians as a key product for wrinkle correction and soft tissue contouring. Juvederm is currently available in three formulations, JUVEDERM 30, JUVEDERM 24 and JUVEDERM 18, which are intended for use in a variety of applications in the dermis, including wrinkles and soft tissue augmentation -- from lip augmentation and superficial lines to frown lines and deep wrinkles.

"The Juvederm products have been very successful in my practice in addressing some of the unmet patient needs in Canada," said Frances Jang, MD, Dermatologist, Clinical Associate Professor, Department of Dermatology, University of British Columbia. "They do not require a skin test, are biocompatible, and have the highest concentration of hyaluronic acid of any filler available today -- meaning they provide optimal aesthetics results and greater lift to the skin. Juvederm gives me flexibility and a strong option in the treatment for facial rejuvenation."

Inamed expects to initiate its clinical development program in the United States and to register the products in Australia in the first half of 2004.

"As the leader in facial rejuvenation, this agreement strengthens our already unmatched portfolio of facial rejuvenation products," said Hani Zeini, Executive Vice President, Inamed Aesthetics. "With the addition of the Juvederm products, Inamed is strategically positioned to provide the most complete range of aesthetic options for patients and physicians -- Zyderm(R)/Zyplast(R) collagen, CosmoDerm(TM)/ CosmoPlast(TM) collagen, Hylaform(R) Gel hyaluronic acid products, and our botulinum toxin Type A product currently in clinical development. No other company offers this breadth of facial rejuvenation products or comprehensive a pipeline."

About Juvederm

Juvederm(R) is a full range of dermal filler products based on non-animal, cross-linked hyaluronic acid technology. This technology is based on the delivery of a homogeneous gel-based HA, as opposed to a particle-gel based HA, which is used in products such as Hylaform(R) Gel and Restylane(R). The homogeneous nature of the Juvederm gel creates less surface area for the body's enzymes to attack and thereby degrade the HA. Currently, Juvederm is available in three formulations, JUVEDERM 30, JUVEDERM 24 and JUVEDERM 18, which are intended for use in a variety of applications in the dermis to treat wrinkles and soft tissue augmentation.

Hyaluronic acid (HA) is a naturally occurring substance (complex sugar) found throughout the body in all living organisms. In the skin, hyaluronic acid fills the space between collagen and elastin fibers -- replenishing the natural support layers lost with aging -- while delivering essential nutrients and hydration.

Juvederm features the highest concentration of hyaluronic acid among existing HA based dermal filler products, including Restylane. In the countries where Juvederm is available, it is approved for a wide range of facial applications, from lip augmentation and superficial lines to frown lines and deep wrinkles.

About Inamed Corporation

Inamed (Nasdaq:IMDC) is a global healthcare company with over 25 years of experience developing, manufacturing and marketing innovative, high-quality, science-based products. Current products include breast implants for aesthetic augmentation and for reconstructive surgery; a range of dermal products to treat facial wrinkles; and minimally invasive devices for obesity intervention, including the Lap-Band System for morbid obesity. The company's website is www.inamed.com.

Forward-Looking Statements

This press release contains, in addition to historical information, forward-looking statements. Such statements are based on management's current estimates and expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Inamed is providing this information as of January 12, 2004, and expressly disclaims any duty to update information contained in this press release.

Forward-looking statements in this press release include, without limitation, express and implied statements regarding Inamed's anticipated research and development, business development, product development, and regulatory approval. These forward-looking statements involve risks and uncertainties which could cause actual results to differ materially from those expressed or implied here. Readers are referred to the documents filed by Inamed with the Securities and Exchange Commission, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements, including but not limited to: exposure to product liability and intellectual property claims; exposure to liabilities that may not be adequately covered by insurance or for which there is no insurance; potential negative publicity concerning product safety; potential fluctuations in quarterly and annual results; the effect of changing accounting and public reporting rules and regulations; volatility of Inamed's stock price; changes in the economy and consumer spending; competition from existing and/or new products; failure or delay of clinical trials; uncertainty in receiving timely regulatory approval or market acceptance for new products; dependence on a single supplier for each of Inamed's silicone raw materials, bovine and human collagen-based products, and hyaluronic acid-based products; failure to protect Inamed's intellectual property; adverse changes in the regulatory or legislative environment (both in the U.S. and internationally) affecting our business; and failure of our collaborative partners to perform.

The information contained in this press release is a statement of Inamed's present intention, belief or expectation and is based upon, among other things, the existing regulatory environment, industry conditions, market conditions and prices, the economy in general and Inamed's assumptions. Inamed may change its intention, belief or expectation, at any time and without notice, based upon any changes in such factors, in Inamed's assumptions or otherwise. Inamed undertakes no obligation to review or confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. By including any information in this press release, Inamed does not necessarily acknowledge that disclosure of such information is required by applicable law or that the information is material.

[Back]
top